UCB nelle notizie
Sviluppo di terapie innovative
Tamtam ha trovato 20 articoli recenti su UCB.
- UCB stock: Kygevvi approval meets fresh BIMZELX evidence
- UCB stock: Kygevvi wins EU approval for rare TK2d disease
- UCB stock gets EU approval for Kygevvi in rare TK2d disease
- UCB's Emmanuel Caeymaex: head-to-head proof, younger patients and a multi-pathway bet on galvokimig
- UCB Announces 11 Inaugural Recipients of Annual Hidradenitis Suppurativa Scholarship™
- Beursupdate: Melexis en UCB trekken de kar in groene Bel20
- Veeva Systems (VEEV) Wins UCB For Vault CRM, Is The Stock Still Cheap?
- UCB stock weighs stronger BIMZELX PsA data against safety signals
- UCB stock weighs BIMZELX joint gains against Candida caveat
- UCB continues reign as largest drug ad spender as Bimzelx once again tops the ranks
- UCB: Bimzelx Retains Its Edge Over Skyrizi at 24 Weeks, on an Exploratory Endpoint
- 'Seal of approval': Rowen seeks more companies after UCB commitment
- De ankeraandeelhouders achter UCB: de voorbeeldige miljardairsfamilie Janssen
- UCB’s Bimzelx leads pharma’s Q3 drug ad spend, but who will take the annual prize?
- Beursblik: Jefferies verhoogt koersdoel UCB
- UCB verhoogt zijn vooruitzichten. De koers schiet omhoog!
- Bel20 uitblinker op rode Europese beurzen, met dank aan jump van UCB
- Brusselse beurs krijgt zuurstofinjectie van UCB
- Farmatoppers UCB en Argenx scheren allebei hoge toppen, maar de belegger reageert compleet anders
- UCB verhoogt outlook voor 2026
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come UCB?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili